The Other Side of Stem Cell Research – The Tablet Catholic Newspaper

(Photo: Getty Images)

By Christopher White, The Tablets National Correspondent

Last month, the federal government implemented a new ban on using fetal tissue for research a move praised by U.S. Catholic leaders.

Yet while the church has long opposed using fetal tissue for research, as it is often derived from abortions, many Catholics are largely unaware that the church supports the use of umbilical cord blood, which is rich in stem cells and has proven effective in many therapies.

Stem cells are special human cells, which can be developed into many types of cells. In 2001, President George W. Bush banned federal funding for embryonic stem cell research a move supported by Catholic leaders as it required the destruction of a human embryo.

Among the ethically acceptable alternatives supported by the church is that of adult stem cell research and using cord blood stem cell transplants, which has proven to be the best way of treating leukemia, sickle cell anemia, Hodgkin lymphoma and a range of other diseases.

In its 2000 document, Declaration on the Production and the Scientific and Therapeutic use of Human Embryonic Stem Cells, the church noted that such a practice offers a more reasonable and human method for making correct and sound progress in this new field of research and in the therapeutic applications which it promises.

These applications are undoubtedly a source of great hope for a significant number of suffering people, the document noted.

Five years later, Cardinal William Keeler, who was then chairman of the United States Conference of Catholic Bishops (USCCB), echoed those words and called for more federal funding to develop a nationwide bank for umbilical cord blood cells.

Umbilical cord blood stem cells have successfully treated thousands of patients with dozens of diseases, Cardinal Keeler said.

They also exhibit properties once associated chiefly with embryonic stem cells: They grow rapidly in culture, producing enough cells to be clinically useful in both children and adults; they can treat patients who are not an exact genetic match, without being rejected as foreign tissue; and they seem able to produce a wide array of different cell types.

What is preventing far broader use of umbilical cord blood stem cells is not an ethical concern, or any lack of evidence of clinical benefits, but simply a lack of funding and access, he lamented at the time.

Jennifer Lahl, a pediatric nurse for more than 20 years and president of the California-based Center for Bioethics and Culture, described the process for The Tablet.

When a baby is born in the hospital delivery room, the umbilical cord blood, which is rich in stem cells, is extracted and saved in a Cord Blood Bank until it is needed to treat a patient, Lahl said.

Parents can make the decision to do private cord blood banking to save the stem cells for use in their own family, but it is more often recommended to store the cord blood stem cells in a public bank, similar to our public blood banks. This makes the stems cells available to anyone who is a match and needs a stem cell transplant, she continued.

Cord blood stem cells are a wonderful resource that should not be tossed out after the delivery of a baby, but saved in order to one day save a life, she added.

Charles Camosy, a theology professor at Fordham University who specializes in medical ethics, noted that the Catholic Church has been a leading proponent of the use of cord blood and has even led the way in working with secular medical institutions to explore their potential.

The Catholic Church has been enthusiastically in support of stem cell research that does not involve embryo-destruction for many years now, he told The Tablet. Indeed, the Vatican has even formally partnered with companies like NeoStem, a U.S.-based biopharmaceutical firm, to see what adult stem cells can do to aid vulnerable sick and disabled people. It turns out, quite a bit. Many therapies have been produced via adult stem cells as well as stem cells from the amniotic fluid of pregnancy. In some cases, it has literally made the blind see.

Yet while developments have offered great promise, he cautioned to carefully discern which companies to use when engaging in treatment.

One should be careful not to be scammed by companies offering to freeze cord blood promising more than can be delivered, he advised. While we still may find new and even dramatic therapies from cord blood stem cells, much of the work has yet to be done.

In 2011, when the Vatican announced its partnership with NeoStem, CEO Dr. Robin Smith said such a partnership offered a way to alleviate human suffering by unlocking the healing power of the human body.

Most importantly, she added, we are able to do all this without destroying another human life.

Read the original post:
The Other Side of Stem Cell Research - The Tablet Catholic Newspaper

Republicans demand answers about government experiments with animals and fetal tissue – Washington Examiner

Republican lawmakers are demanding the Trump administration provide more information about government experiments that mix animals with fetal tissue from abortions.

In a letter sent Wednesday, 69 lawmakers said they were "disappointed" the research had been allowed to continue and highlighted a Washington Examiner op-ed from August that said the National Institutes of Health, the government's research branch, paid out $115 million for 200 different projects involving fetal tissue.

The op-ed was written by Terrisa Bukovinac, founder and executive director of Pro-Life San Francisco, and by Alyssa Canobbio Hackbarth, a board member for an anti-animal experimentation group called the White Coat Waste Project. They describe experiments in which scientists were "implanting thymus glands from aborted human babies into mice" and "dissecting kidney tissue from 8 to 18-week-old human fetuses."

The Republicans asked Alex Azar, the Health and Human Services secretary, to send more information about the grants and what fetal parts they use, and about which ones also used animals. They also asked for more information about the ethics board the NIH said it would create to devise a system for reviewing grants that involve the tissue.

The NIH announced in June that it would no longer let government scientists conduct experiments using any new fetal tissue acquired from abortions. It did not, however, put a stop to the research already underway or stop outside groups that receive the funding from conducting the research.

The decision came after months of backlash from anti-abortion groups, who demanded President Trump fire NIH Director Francis Collins for saying that research using fetal tissue could provide useful study for treatments of devastating illnesses.

At the same time, some members of Congress are pressuring government agencies to look for alternatives to animal experimentation whenever possible. The Environmental Protection Agency has pledged not to use any mammals for research starting in 2035.

Still, animal experimentation is common. Any prescription drug that has been approved by the Food and Drug Administration first had to clear animal testing before scientists moved onto trials involving people.

Republicans have called for ending fetal tissue research since the anti-abortion Center for Medical Progress released videos that appeared to show Planned Parenthood staff discussing the sale of fetal tissue, a practice that is illegal. Planned Parenthood has denied wrongdoing, and state investigations have not found evidence that the organization illegally sold fetal tissue for profit.

Outside groups opposed to fetal tissue research are not just opposed to abortion, but contend the practice of using the tissue in experiments is degrading, wrong, and unnecessary. They question whether fetal tissue research is effectual and believe other types of tissues work better and should be used instead adult stem cells, umbilical cord, amniotic fluid, tissue from the placenta, or discarded tissue from surgery on an infant. Major medical groups defend the research and say fetal tissue has unique properties that will help scientists develop cures to infectious and chronic diseases.

View original post here:
Republicans demand answers about government experiments with animals and fetal tissue - Washington Examiner

Reviewing MediciNova Inc. (MNOV)’s and Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI)’s results – MS Wkly

MediciNova Inc. (NASDAQ:MNOV) and Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) compete with each other in the Biotechnology sector. We will analyze and compare their dividends, analyst recommendations, profitability, institutional ownership, risk, earnings and valuation.

Earnings and Valuation

Table 1 shows top-line revenue, earnings per share and valuation of the two companies.

Profitability

Table 2 shows us MediciNova Inc. and Brainstorm Cell Therapeutics Inc.s net margins, return on assets and return on equity.

Risk and Volatility

A beta of 1.18 shows that MediciNova Inc. is 18.00% more volatile than Standard and Poors 500. Brainstorm Cell Therapeutics Inc. has a 1.19 beta and it is 19.00% more volatile than Standard and Poors 500.

Liquidity

The Current Ratio and Quick Ratio of MediciNova Inc. are 34.8 and 34.8 respectively. Its competitor Brainstorm Cell Therapeutics Inc.s Current Ratio is 1 and its Quick Ratio is 1. MediciNova Inc. can pay off short and long-term obligations better than Brainstorm Cell Therapeutics Inc.

Analyst Ratings

The table given features the ratings and recommendations for MediciNova Inc. and Brainstorm Cell Therapeutics Inc.

Meanwhile, Brainstorm Cell Therapeutics Inc.s consensus price target is $9, while its potential upside is 127.85%.

Institutional and Insider Ownership

Roughly 21.3% of MediciNova Inc. shares are owned by institutional investors while 11.4% of Brainstorm Cell Therapeutics Inc. are owned by institutional investors. About 2.7% of MediciNova Inc.s share are owned by insiders. Competitively, 0.6% are Brainstorm Cell Therapeutics Inc.s share owned by insiders.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

For the past year MediciNova Inc.s stock price has bigger growth than Brainstorm Cell Therapeutics Inc.

Summary

MediciNova Inc. beats on 7 of the 11 factors Brainstorm Cell Therapeutics Inc.

MediciNova, Inc., a biopharmaceutical company, focuses on acquiring and developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The companys product candidate includes MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for the treatment of neurological disorders, including primary and secondary progressive multiple sclerosis; amyotrophic lateral sclerosis; and substance dependence and addiction, including methamphetamine, opioid, and alcohol dependence. Its product pipeline also comprises MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic diseases, such as nonalcoholic steatohepatitis, idiopathic pulmonary fibrosis, and other fibrotic diseases; MN-221 (bedoradrine), a 2-adrenergic receptor agonist for the treatment of acute exacerbation of asthma; and MN-029 (denibulin), a tubulin binding agent to treat solid tumor cancers. The company was founded in 2000 and is headquartered in La Jolla, California.

Brainstorm Cell Therapeutics Inc., a biotechnology company, develops adult stem cell therapies for neurodegenerative disorders that include amyotrophic lateral sclerosis, multiple sclerosis, Parkinsons disease, and others. The company holds rights to develop and commercialize its NurOwn technology through a licensing agreement with Ramot of Tel Aviv University Ltd. Its NurOwn technology is based on a novel differentiation protocol, which induces differentiation of the bone marrow-derived mesenchymal stem cells into neuron-supporting cells and secreting cells that release various neurotrophic factors, including glial-derived neurotrophic factor, brain-derived neurotrophic factor, vascular endothelial growth factor, and hepatocyte growth factor for the growth, survival, and differentiation of developing neurons. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004 to reflect its new line of business in the development of novel cell therapies for neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was founded in 2000 and is headquartered in Hackensack, New Jersey.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Original post:
Reviewing MediciNova Inc. (MNOV)'s and Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI)'s results - MS Wkly

SI-BONE Inc. (SIBN) and Cesca Therapeutics Inc. (NASDAQ:KOOL) Comparing side by side – MS Wkly

SI-BONE Inc. (NASDAQ:SIBN) and Cesca Therapeutics Inc. (NASDAQ:KOOL) compete with each other in the Medical Appliances & Equipment sector. We will analyze and contrast their risk, analyst recommendations, profitability, dividends, earnings and valuation, institutional ownership.

Valuation and Earnings

Table 1 shows the top-line revenue, earnings per share (EPS) and valuation for SI-BONE Inc. and Cesca Therapeutics Inc.

Profitability

Table 2 shows SI-BONE Inc. and Cesca Therapeutics Inc.s return on equity, net margins and return on assets.

Liquidity

SI-BONE Inc. has a Current Ratio of 13.1 and a Quick Ratio of 12.7. Competitively, Cesca Therapeutics Inc.s Current Ratio is 1.6 and has 0.8 Quick Ratio. SI-BONE Inc.s better ability to pay short and long-term obligations than Cesca Therapeutics Inc.

Analyst Ratings

The table given features the ratings and recommendations for SI-BONE Inc. and Cesca Therapeutics Inc.

Meanwhile, Cesca Therapeutics Inc.s consensus target price is $7.5, while its potential upside is 45.07%.

Insider & Institutional Ownership

The shares of both SI-BONE Inc. and Cesca Therapeutics Inc. are owned by institutional investors at 74.7% and 1.8% respectively. About 3% of SI-BONE Inc.s share are held by insiders. Insiders Comparatively, held 30.91% of Cesca Therapeutics Inc. shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

For the past year SI-BONE Inc. had bearish trend while Cesca Therapeutics Inc. had bullish trend.

Summary

SI-BONE Inc. beats on 7 of the 9 factors Cesca Therapeutics Inc.

SI-BONE, Inc., a medical device company, develops and commercializes a proprietary minimally invasive surgical implant system in the United States and Internationally. It offers iFuse, an implant system to fuse the sacroiliac joint to treat sacroiliac joint dysfunction that causes lower back pain. The company was founded in 2008 and is headquartered in Santa Clara, California.

Cesca Therapeutics Inc. focuses on the research, development, and commercialization of autologous cell-based therapeutics for use in regenerative medicine in the United States and internationally. The company develops and manufactures automated blood and bone marrow processing systems that enable the separation, processing, and preservation of cell and tissue therapy products. Its products include SurgWerks system, a proprietary system comprised of the SurgWerks processing platform, including devices and analytics, and indication-specific SurgWerks procedure kits for use in regenerative stem cell therapy at the point of care for vascular and orthopedic diseases; CellWerks system, a proprietary cell processing system with associated analytics for intra-laboratory preparation of adult stem cells from bone marrow or blood; and AutoXpress system, a proprietary automated device and companion sterile disposable for concentrating hematopoietic stem cells from cord blood. The company also offers MarrowXpress system, a derivative product of the AXP and its accompanying sterile disposable for the isolation and concentration of hematopoietic stem cells from bone marrow; BioArchive system, an automated cryogenic device used by cord blood banks for the cryopreservation and storage of cord blood stem cell concentrate for future use; and manual disposables bag sets for use in the processing and cryogenic storage of cord blood. In addition, it provides cell manufacturing and banking services. The company was formerly known as ThermoGenesis Corp. and changed its name to Cesca Therapeutics Inc. in February 2014. Cesca Therapeutics Inc. was founded in 1986 and is headquartered in Rancho Cordova, California.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Go here to see the original:
SI-BONE Inc. (SIBN) and Cesca Therapeutics Inc. (NASDAQ:KOOL) Comparing side by side - MS Wkly

Inherited Learning? It Happens, but How Is Uncertain – Quanta Magazine

Rechavi says that exactly how the changes in the neurons are communicated to the germline and how thataffects the nervous system of the next generation are still open questions. He hypothesizes that the process involves one or more molecules released by the nervous system perhaps small RNAs, perhaps something secreted like a hormone. But somehow those germ cells then influence the behavior of the next generation and seem to circumvent the normal need for rde-4 in the production of the small RNAs for chemotaxis in the progeny.

In another paper on epigenetic behavior that appeared in the same June issue of Cell, Rebecca Moore, Rachel Kaletsky and Coleen Murphy, the molecular biologist who leads their laboratory at Princeton University, reported that C. elegans worms exposed to the pathogenic bacterium Pseudomonas aeruginosa learn to avoid it, and they transmit this learned avoidance for approximately four generations. Normally, the worms seem to prefer Pseudomonas to the bacteria on which they routinely feed.

The researchers sought to understand how this behavior is controlled at a molecular level. They discovered that double-stranded RNA from the pathogen triggered the worms response, a finding that they further investigated with Lance Parsons of Princeton University and described in a biorxiv preprint posted on July 11.

In the worms exposed to the pathogen, they detected changes in the expression of a gene, daf-7, in a specific neuron called ASI that is required for the avoidance behavior. They also found a huge number of changes in the small RNAs in the germline, Murphy said, including the ones called Piwi-interacting RNA (piRNA). As the name suggests, piRNAs interact with piwi genes, which help to regulate stem cell differentiation.

Moore, Kaletsky and Murphy found that animals without the piRNA pathway can learn to avoid Pseudomonas but do not pass on this avoidance behavior to their progeny. Thus, the piRNA pathway is critical for inheritance of the behavior. Thats why were excited about the piRNA pathway, Murphy said.

Sarkies thinks these findings may help to explain the curious ability of C. elegans to take up double-stranded RNA from the environment and use it to silence endogenous genes. For years, geneticists have exploited this property of worms: By synthesizing double RNAs that match any gene, researchers can silence it and study what it does.

But why the worm has this ability was mysterious. It obviously didnt evolve it in order to make life easy for scientists, and we dont really understand what ecological role it might have, Sarkies said. Whats quite exciting in principle about the studies from the Murphy lab is that they suggest that this might be a way in which C. elegans is able to adapt to pathogenic bacteria. Hypothetically, when the worm takes up double-stranded RNA from bacteria in its environment, the molecules could silence some of the worms genes and induce adaptive responses. Those adaptations could then be passed to the next generation.

Most in the field still approach such conjectures with skepticism. I believe that today, there is not a single solid paper showing that only small RNAs are involved in epigenetic inheritance, said Isabelle Mansuy, a neuroepigenetics researcher at the Swiss Federal Institute of Technology Zurich and the University of Zurich who studies the inheritance of trauma in humans and mice. In the mouse model she works with, she knows that small RNAs are not sufficient because if she injects small RNAs alone into fertilized mouse eggs, the resulting animals do not show the RNA-associated trait.

Mansuy believes that a multitude of factors may contribute in different ways to epigenetic inheritance, and their importance may vary with the trait or behavior. Very often people like to simplify the matter and think either its DNA methylation or its microRNA. I think its totally misleading to think that way, she said. People should not dismiss one or the other but just think about all these factors together.

She added that errors have crept into the literature on epigenetic inheritance, making some findings seem more definitive than they are. For example, some review articles claim that Mansuy demonstrated that injecting microRNAs into fertilized eggs is sufficient to cause the inheritance of behavioral symptoms in mice. We never showed this, she emphasized. Authors of review articles often dont go back to check the original findings, so when the review is cited subsequently, it creates an auto-feeding system that perpetuates errors. Its polluting the field, she said. Now many people work only on RNA epigenetic inheritance because they think it is well established, she added.

Unreliable findings have also sometimes appeared in high-profile journals. As a result, she argues, the field as a whole may be on thinner ice than it seems. The lack of rigor can lead to a misleading thought and perception, she warned.

Validation of Mansuys skepticism can be found in a recent study in eLife on epigenetic inheritance in fruit flies. Giovanni Bosco and his colleagues at Dartmouth College demonstrated that learned adaptive behaviors in fruit flies can be epigenetically inherited but that small RNAs are not sufficient to transmit this behavior.

In Drosophila, adult females raised with parasitic wasps learn to lay their eggs on food that contains ethanol, which protects the eggs and larvae from being parasitized by the wasps. This egg-laying preference occurs even when the mother herself was never exposed to ethanol, Bosco emphasized. Exposure to the wasp was in and of itself sufficient for the females to somehow epigenetically reprogram their eggs so that their daughters would be predisposed to have this behavior, he said.

The preference for egg laying on ethanol persists for five generations. Bosco, his graduate student Julianna Bozler, and Balint Kacsoh (now a postdoc at the University of Pennsylvania) hypothesized that small RNAs were involved in the inheritance of this behavior. To test this idea, they used a quirk of fly genetics to create flies with a pair of chromosomes that both came from the same parent (normally, both parents contribute to each pair). Boscos team reasoned that if small RNAs in the cytoplasm of the mothers egg were sufficient for inheritance of the learned behavior, then the offspring should exhibit the inherited behavior even if it received both pairs of chromosomes from the father.

In a series of experiments, Bozler, Kacsoh and Bosco demonstrated that small noncoding RNAs from the mother were not sufficient for transmitting the behavior between generations; an as yet unidentified epigenetic modification on chromosome 3 was also essential. They are currently investigating the nature of this epigenetic change.

To Bosco, the big question is: How does the signal from the brain reach an egg and change the information thats in the egg? Figuring this out would open the floodgates to ask: What else is the brain doing to the germline? What else are our cognitive experiences and environmental exposures impinging on the epigenome of the egg or sperm?

Most people, Bosco continued, would have no trouble accepting that exposure to a toxic chemical in our water or food could interact with the germline and change the epigenetic state of germ cells.

What I would suggest is that our brains are our pharmacies, Bosco said. Our brains are making chemicals all the time, such as neuropeptides and other neuromodulatory molecules with diverse functions. Some of those functions impinge directly on processes in other organs, including the reproductive system. If we can ingest a chemical from our environment that changes the epigenomes of the egg or sperm, why couldnt our brain make a similar molecule that does the same thing? he said.

At Cambridge, Burton has identified at least one of the ways in which information from the nervous system can be transmitted to the germline. In a 2017 Nature Cell Biology paper, he and his colleagues exposed C. elegans to high levels of salt to induce a state called osmotic stress. They discovered that the worms brain responded by secreting insulin-like peptides that change the egg-making cells (oocytes) in ways that induce an epigenetic change. The resulting alterations in gene expression in the oocytes lead the offspring to produce more glycerol, which protects them against osmotic stress.

You have a neuronal signal affecting the germ cells that looks to be adaptive, Burton said.

Mansuy has found that early-life trauma in mice leads to the release of stress hormones that affect the animal throughout its life span, producing depressed or risk-taking behaviors, metabolic dysregulation, and other health problems. They also affect the developing germ cells, causing the same behaviors and metabolic alterations to be inherited in the offspring for up to five generations. Previously, Mansuy had found that small RNAs were not sufficient to transmit these phenotypes in mice, just as they were not sufficient in the fruit flies. Something else was going on.

In a preprint recently posted on biorxiv.org, she and her colleagues report that by injecting the blood of traumatized mice into control mice, they could induce similar metabolic symptoms. The injected blood also appeared to affect the mices germ cells because their offspring inherited the metabolic abnormalities too.

The researchers identified some of the signaling molecules that transmitted the metabolic effects as fatty acids that can bind to receptor molecules, move into the nucleus and help activate the transcription of certain targeted genes. The receptors exist in germ cells, too, so they could be one of the ways in which information moves between blood and germ cells, Mansuy suggests.

One of the outstanding questions in the field is why epigenetic inheritance only lasts for a handful of generations and then stops, said Eric Greer, an epigeneticist at Harvard Medical School and Boston Childrens Hospital who studies the epigenetic inheritance of longevity and fertility in C. elegans. It appears to be a regulated process, in part because the effect persists at the same magnitude from one generation to the next, and then abruptly disappears. Moreover, in a paper published in Cell in 2016, Rechavi and colleagues described dedicated cell machinery and specific genes that control the duration of the epigenetically inherited response. So its an evolved mechanism that likely serves many important functions, Rechavi said.

But what exactly is adaptive about it? If the response is adaptive, why not hardwire it into the genome, where it could be permanently and reliably inherited?

In Murphys C. elegans model, because the learned avoidance behavior is transient (even if it is transgenerational), it allows animals to go back to eating bacteria that are nutritious but smell a lot like those pathogens, she explained. Sniffing out the difference between food and foes can be difficult, so worms that permanently avoid pathogens will miss out on nutritious food sources.

Greer concurs that there could generally be a cost to deploying an adaptive response permanently. For example, deploying antiviral defenses when pathogens arent around is a waste of resources that could be used instead for growth and reproduction.

Trade-offs could also constrain other adaptations. In Burtons 2017 study, worms exposed to P. aeruginosa produced offspring resistant to the pathogen, but that adaptation was deleterious to the offsprings ability to respond to other challenges, like osmotic stress. Unavoidable trade-offs between adaptations to different stresses make it impossible for the worms to be optimally adapted across the board.

In that scenario, you wouldnt want it hardwired into your genetics. Youd want this plasticity where you could program the adaptation, but also get rid of it, Burton explained. That may explain why stress appears to reset transgenerational small-RNA inheritance, as reported by Rechavi and his colleagues in a new preprint on biorxiv.org.

Very little work has been done to investigate mismatched stresses between parents and offspring, but a lot of literature suggests that these mismatched stresses might play a role in human diseases, Burton said. I think mechanistically looking at that is going to be really interesting, going forward.

Correction added on Oct. 16, 2019: The beginning of one sentence was rephrased to clarify that the described work in Murphys lab was not related to Rechavis experiments.

Read the original:
Inherited Learning? It Happens, but How Is Uncertain - Quanta Magazine

Contrasting of Brainstorm Cell Therapeutics Inc. (BCLI) and Magenta Therapeutics Inc. (NASDAQ:MGTA) – MS Wkly

As Biotechnology companies, Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) and Magenta Therapeutics Inc. (NASDAQ:MGTA) are our subject to contrast. And more specifically their risk, analyst recommendations, profitability, dividends, institutional ownership, earnings and valuation.

Valuation and Earnings

Table 1 highlights Brainstorm Cell Therapeutics Inc. and Magenta Therapeutics Inc.s gross revenue, earnings per share (EPS) and valuation.

Profitability

Table 2 shows us Brainstorm Cell Therapeutics Inc. and Magenta Therapeutics Inc.s net margins, return on equity and return on assets.

Liquidity

The Current Ratio of Brainstorm Cell Therapeutics Inc. is 1 while its Quick Ratio stands at 1. The Current Ratio of rival Magenta Therapeutics Inc. is 17.1 and its Quick Ratio is has 17.1. Magenta Therapeutics Inc. is better equipped to clear short and long-term obligations than Brainstorm Cell Therapeutics Inc.

Analyst Recommendations

In next table is given Brainstorm Cell Therapeutics Inc. and Magenta Therapeutics Inc.s ratings and recommendations.

Brainstorm Cell Therapeutics Inc. has a 126.70% upside potential and an average price target of $9.

Institutional & Insider Ownership

Institutional investors owned 11.4% of Brainstorm Cell Therapeutics Inc. shares and 85.4% of Magenta Therapeutics Inc. shares. 0.6% are Brainstorm Cell Therapeutics Inc.s share owned by insiders. Comparatively, 2.2% are Magenta Therapeutics Inc.s share owned by insiders.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

For the past year Brainstorm Cell Therapeutics Inc.s stock price has smaller growth than Magenta Therapeutics Inc.

Brainstorm Cell Therapeutics Inc., a biotechnology company, develops adult stem cell therapies for neurodegenerative disorders that include amyotrophic lateral sclerosis, multiple sclerosis, Parkinsons disease, and others. The company holds rights to develop and commercialize its NurOwn technology through a licensing agreement with Ramot of Tel Aviv University Ltd. Its NurOwn technology is based on a novel differentiation protocol, which induces differentiation of the bone marrow-derived mesenchymal stem cells into neuron-supporting cells and secreting cells that release various neurotrophic factors, including glial-derived neurotrophic factor, brain-derived neurotrophic factor, vascular endothelial growth factor, and hepatocyte growth factor for the growth, survival, and differentiation of developing neurons. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004 to reflect its new line of business in the development of novel cell therapies for neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was founded in 2000 and is headquartered in Hackensack, New Jersey.

Magenta Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing medicines to bring the curative power of bone marrow transplant to patients. It is developing C100, C200, and C300 targeted antibody-drug conjugates for transplant conditioning; MGTA-145, a stem cell mobilization product candidate to control stem cell mobilization; MGTA-456, an allogeneic stem cell therapy to control stem cell growth; E478, a small molecule aryl hydrocarbon receptor antagonist for the expansion of gene-modified stem cells; and G100, an ADC program to prevent acute graft and host diseases. The company was formerly known as HSCTCo Therapeutics, Inc. and changed its name to Magenta Therapeutics, Inc. in February 2016. Magenta Therapeutics, Inc. was incorporated in 2015 and is based in Cambridge, Massachusetts.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Read this article:
Contrasting of Brainstorm Cell Therapeutics Inc. (BCLI) and Magenta Therapeutics Inc. (NASDAQ:MGTA) - MS Wkly

PRP and IRAP: Where nature meets science in horse injury treatment – Horsetalk.co.nz – Horsetalk

Platelet Rich Plasma is injected into an injured area to encourage a morerobust healing response.Palm Beach Equine Clinic

As sport horses become faster and stronger, veterinary medicine is often challenged to break barriers to provide the best in diagnostic and maintenance care.

Two resources that have become increasingly popular to treat equine injuries are Platelet Rich Plasma (PRP) and Interleukin-1 Receptor Antagonist Protein (IRAP), which encourage regeneration of injured or degenerative tissue.

Managing joint diseases and injuries using these methods is ground-breaking, but logical at its core. They essentially use naturally occurring proteins, cells, and other natural processes originated from within the body of the horse to put the horses own biological mechanisms to work stimulating healing without the use of steroids or other drugs.

Platelets are among the very first cells to accumulate at an injured site, making them very important when simulating the repair process. Platelets contain granules filled with growth factors (the elements that aid in healing) and stimulate specified tissue to heal at an increased rate. To treat a horse with PRP, the veterinarians at PBEC are able to take a sample of the horses blood and concentrate the platelets in a high-speed centrifuge on-site. The harvest and processing procedures take approximately 30 minutes before the concentrated platelet-rich sample is injected back into the horse at the specific area of injury using sterile techniques and guided by ultrasound.

Explaining the process, Dr Weston Davis, Board-Certified Staff Surgeon at Floridas Palm Beach Equine Clinic, said that first, a large quantity of blood is harvested, anywhere from 60 to180ml.

We process that to concentrate the segment that is very rich in platelets. We get a high concentration of platelets we are hoping for five to eight times the concentration that you would get from normal blood. Then we take that platelet-rich extract and inject it back into an injured area to encourage a more robust healing response.

Whenever you have an injury, platelets are one of the first cells that get there. They will aggregate, clump, and de-granulate. They release granules that are very rich in growth factors and signal the body to start the healing process.

IRAP is used to treat equine athletes that are susceptible to musculoskeletal injuries and osteoarthritis or degenerative joint disease. Joint trauma results in the release of inflammatory mediators such as Interleukin-1 (IL-1). IRAP uses a horses own anti-inflammatory protein found within the blood to counteract the destructive effects of IL-1 to slow the process of osteoarthritis. The process works by binding to the IL-1 receptors in the joint and blocking the continuation of damage and inflammation.

Palm Beach Equine Clinic veterinarian Dr Bryan Dubynsky said veterinarians often see joint damage in sport horses because of the nature of their work. But we try to avoid over-use of steroids in joints because steroids can have long-term effects on cartilage.

This is a way we can manage joint disease and stop inflammation without having to consistently use steroids. Some of our clients will maintain their horses on IRAP alone for joint injections.

The goal to better serve sport horses that continue to improve athletically is the driving force behind the search for even more developed and precise techniques used in regenerative medicine.

I believe we are learning more about these technologies with more advanced science behind what they do and how they do it, Dubynsky said. These treatments are natural, drug-free, and competition-safe, and necessity drives the need for regenerative therapies in the sport horse world.

Read the original here:
PRP and IRAP: Where nature meets science in horse injury treatment - Horsetalk.co.nz - Horsetalk

Protective mediators help heal tendon cells by attacking inflammation – Health Europa

Tendon tears, both to the rotator cuff and Achilles heel, are common injuries, especially in aged individuals. Painful and disabling, they can adversely impact quality of life.

New approaches are required to help patients suffering from chronic tendon injuries. A novelstudyinThe American Journal of Pathology, identified mediators that promote resolution of inflammation as potential new therapeutics to push chronically injured tendons down an inflammation-resolving pathway.

Stephanie Dakin of Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Botnar Research Centre and University of Oxford, said: Our study informs new therapeutic approaches that target diseased cells and promote resolution of tendon inflammation, harnessing the bodys own natural responses for therapeutic gain.

The study demonstrates the anti-inflammatory effects of two specialised pro-resolving mediators (SPMs), lipoxin B4 (LXB4) and Resolvin E1 (RvE1), on cultured tendon cells in which induced shoulder tendon disease was present.

According to Dr Dakin and colleagues, resident (meaning part of the normal tissue) stromal cells, especially fibroblasts, play a pivotal role in inflammatory diseases of joints. After injury, fibroblasts become activated and show inflammation memory, an important event underlying the switch from acute to chronic inflammation.

These cells become unable to return to their normal state. The SPMs identified by the researchers interfere with this chronic inflammatory process and help fibroblasts resolve tendon inflammation; hence the name pro-resolving mediators.

Commenting on the study, Undurti N Das of UND Life Sciences, Battle Ground and BioScience Research Centre and Department of Medicine, GVP Medical College and Hospital, Visakhapatnam, India, emphasised that understanding the crosstalk among resident stromal cells including fibroblasts that not only participate in inflammatory diseases of the joint, but also in the switch from acute to chronic inflammation, tissue resident and infiltrating macrophages, infiltrating immune cells, and endothelial cells is important to the disease process and for the development of newer therapeutic interventions.

Dr Das said: In this context, the report by Dakin et al is of substantial interest to the field. It establishes that tendon stromal cells isolated from patients with tendon tears show pro-inflammatory phenotype and secrete significantly higher amounts of interleukin (IL)-6 with dysregulated production and action of lipoxin A4, resolvins, protectins, and maresins compared to normal cells.

Dr Dakin said: There is a clear unmet clinical need to develop effective new therapeutic approaches to treat tendon disease.

SPMs, including LXB4 and RvE1, may target diseased cells and potentiate resolution of chronic tendon inflammation.

Shoulder pain is the third most common cause of musculoskeletal pain, and tears affecting shoulder rotator cuff tendons comprise a large proportion of this disease burden. Current treatments for tendon injuries include physical therapy, non-steroidal anti-inflammatory drugs, platelet rich plasma, steroid injections, and surgery to repair torn tendons.

These therapies are frequently ineffective, steroids are potentially harmful, and tendon tear surgery is associated with high postoperative failure rates. Therefore, alternative therapies targeting the cells driving chronic inflammation are required to help patients, and ideally avoid some of the problems associated with surgery, steroids, NSAIDS, or other interventions.

Here is the original post:
Protective mediators help heal tendon cells by attacking inflammation - Health Europa

WindMIL Therapeutics and University of California, Irvine Announce Collaboration to Collect Bone Marrow from Patients with Gliomas to Develop Marrow…

BALTIMOREand PHILADELPHIA and IRVINE, Calif., Oct. 15, 2019 (GLOBE NEWSWIRE) -- WindMIL Therapeutics and the University of California, Irvine (UCI) today announced that the first patients have been identified in an investigator-sponsored study for the collection of bone marrow from patients with gliomas. The study will evaluate generating marrow infiltrating lymphocytes (MILs) for these patients through WindMILs proprietary cellular activation and expansion process. The study is being conducted at UCI.

Patients suffering with glioblastoma are in great need of new, promising treatments that might advance the current standard of care, said Daniela A. Bota, MD, PhD, director of theUCI Health Comprehensive Brain Tumor Program,seniorassociate dean for clinical research, UCI School of Medicine and clinical director, UCI Sue & Bill Gross Stem Cell ResearchCenter. The University of California, Irvine is excited toplay a key role in research that may lead to a clinical trial that enlists the immune system in novel ways to fight this terrible disease.

Gliomas are the most common of the malignant brain tumors. Glioblastoma, the most common glioma, has a five-year survival of less than 5 percent. Additional treatment options are urgently needed for these patients. Adoptive immunotherapy is a possible approach for gliomas and the use of MILs, a cell therapy that is naturally tumor-specific, is one such treatment option.

The bone marrow is a unique niche in the immune system to which antigen-experienced memory T cells traffic and are then maintained. WindMIL has developed a proprietary process to select, activate and expand these memory T cells into MILs. Because memory T cells in bone marrow occur as a result of the immune systems recognition of tumor antigens, MILs are specifically suited for adoptive cellular immunotherapy and are able to directly eradicate or facilitate eradication of each patients unique cancer. WindMIL is currently studying MILs in multiple myeloma, non-small cell lung cancer and squamous cell carcinoma of the head and neck, and plans to expand into other solid tumors.

WindMIL is looking forward to working with the University of California, Irvine on this exciting project and is optimistic that MILs may offer the potential to help patients with these hard-to-treat diseases, said Monil Shah, PharmD, MBA, Chief Development Officer at WindMIL.

About WindMIL Therapeutics

WindMIL Therapeutics is a clinical-stage company developing a novel class of autologous cell therapies based on marrow infiltrating lymphocytes (MILs) for cancer immunotherapy. As the leader in cellular therapeutics emanating from bone marrow, WindMIL translates novel insights in bone marrow immunology into potentially life-saving cancer immunotherapeutics for patients. WindMIL believes that Cell Source Matters and the companys proprietary process to extract, activate and expand these cells offers unique immunotherapeutic advantages, including inherent poly-antigen specificity, high cytotoxic potential and long persistence. For more information, please visit: http://www.windmiltx.com.

About UCI Health

UCI Healthcomprises the clinical enterprise of the University of California, Irvine. Patients can access UCI Health at primary and specialty care offices across Orange County and at its main campus, UCI Medical Center in Orange, California. The 417-bed acute care hospital provides tertiary and quaternary care, ambulatory and specialty medical clinics and behavioral health and rehabilitation services. UCI Medical Center features Orange Countys only National Cancer Institute-designated comprehensive cancer center, high-risk perinatal/neonatal program and American College of Surgeons-verified Level I adult and Level II pediatric trauma center and regional burn center. UCI Health serves a region of nearly 4 million people in Orange County, western Riverside County and southeast Los Angeles County. Follow us onFacebookandTwitter.

About the University of California, Irvine

Founded in 1965, UCI is the youngest member of the prestigious Association of American Universities. The campus has produced three Nobel laureates and is known for its academic achievement, premier research, innovation and anteater mascot. Led by Chancellor Howard Gillman, UCI has more than 36,000 students and offers 222 degree programs. Its located in one of the worlds safest and most economically vibrant communities and is Orange Countys second-largest employer, contributing $5 billion annually to the local economy. For more on UCI, visitwww.uci.edu.

Story continues

Read the rest here:
WindMIL Therapeutics and University of California, Irvine Announce Collaboration to Collect Bone Marrow from Patients with Gliomas to Develop Marrow...

Benefit of CD19-Targeted CAR-T Therapy in Patients With Transformed Waldenstrm Macroglobulinemia – Cancer Therapy Advisor

A case study published in Leukemia and Lymphoma described a patient with a diagnosis of Waldenstrm Macroglobulinemia (WM) that had subsequently undergone histological transformation to refractory high grade B-cell lymphoma and was successfully treated with CD19-targeted chimeric antigen receptor (CAR)-T cell therapy.1

WMis a type of B-cell non-Hodgkin lymphoma(NHL), typically characterized by overproduction of monoclonal immunoglobulinM, as well as infiltration of malignant lymphoplasmacytic cells into the bonemarrow.

Although considered incurable, WM often follows an indolent course andsome patients can be asymptomatic for long periods. Rarely, the diseasetransforms into a more aggressive form of NHL that has been associated with apoor prognosis.

The patient described in the case studywas a 71-year-old man who was first diagnosed with WM in 1998. The patient wasmonitored without undergoing active treatment for a period of 12 years, atwhich time he developed anemia and splenomegaly. At that time, he underwenttreatment with 6 cycles of fludarabine and rituximab and achieved a partial response totreatment. Following a worsening of symptoms 4 years later, the patient wastreated with 6 cycles of bendamustine and rituximab.

Biopsyof an enlarged cervical lymph node performed at that time revealed high-gradeB-cell lymphoma that was clonally related to the previously seenlymphoplasmacytic infiltrate, consistent with transformation.

Thepatient subsequently achieved a complete response to 6 cycles of rituximab,cyclophosphamide, doxorubicin, vincristine, prednisone (R-CHOP) plus ibrutinibfollowed by 6 months of ibrutinib maintenance therapy that lasted for 18months.

Salvagetherapy included 2 cycles of rituximab, dexamethasone, cytarabine, cisplatin(R-DHAP) followed by 1 cycle of rituximab plus high-dose cytarabine, followedby autologous stem cell transplantation several months later.

Asthe patients disease was considered to be chemorefractory based on subsequent imagingand pathological analyses, he was treated with axicabtagene ciloleucel, aCD19-targeted CAR-T cell therapy currently approved for the treatment of adultpatients with relapsed or refractory large B-cell lymphoma, including high gradeB-cell lymphoma, after 2 or more lines of systemic therapy.2

Althoughthe patient experienced pancytopenia, grade 1 cytokine release syndrome, andgrade 1 neurotoxicity following CAR-T therapy, he achieved a complete response1 month following treatment.

Notably,there was no evidence of either underlying WM or transformed disease at 6 and 12months follow-up.

Thestudy authors noted that longer term follow up in this patient will beinformative, as late relapses have occurred even in patients who achieve a deepresponse after transplant. CAR-T cell therapy may be an effective treatment forrelapsed or refractory WM that has not yet undergone histologicaltransformation, as CD19 is almost universally expressed on lymphoplasmacyticlymphoma cells. The researchers concluded that further analysis of this iswarranted in the context of clinical trials.

References

Read more:
Benefit of CD19-Targeted CAR-T Therapy in Patients With Transformed Waldenstrm Macroglobulinemia - Cancer Therapy Advisor